Founded in 1978, Biogen is the world’s oldest independent biotech and a Fortune 500 company with more than $5 billion in annual revenues. Patients worldwide benefit from Biogen’s leading multiple sclerosis therapies, such as AVONEX® and TYSABRI®, and through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Neurimmune has realized its aim of efficiently advancing leading RTM-based immunotherapy programs for the benefit of Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disease patients.

Biogen Corporate Overview
Presentation at the 31st J.P.Morgan Healthcare Conference